{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:42:16Z","timestamp":1790685736363,"version":"4.1.0"},"reference-count":153,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006464","name":"Birla Institute of Technology and Science, Pilani","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006464","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.jconrel.2020.05.022","type":"journal-article","created":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T18:20:43Z","timestamp":1590344443000},"page":"379-404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs"],"prefix":"10.1016","volume":"324","author":[{"given":"Dhanashree H.","family":"Surve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil B.","family":"Jindal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2020.05.022_bb0005","series-title":"Antiretroviral Drug Discovery and Development","first-page":"3","year":"2020"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0010","series-title":"Global HIV & AIDS statistics \u2014 2019 fact sheet","author":"UNAIDS","year":"2020"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0015","author":"HIV\/AIDS"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12877-019-1335-4","article-title":"Knowledge of HIV\/AIDS among older adults (50 years and above) in a peri-urban setting: a descriptive cross-sectional study","volume":"19","author":"Anokye","year":"2019","journal-title":"BMC Geriatr."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0025","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2174\/187152611795589663","article-title":"HIV treatment adherence, drug resistance, virologic failure: evolving concepts","volume":"11","author":"Nachega","year":"2011","journal-title":"Infect Disord Drug Targets"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0030","author":"Roser"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/COH.0000000000000510","article-title":"Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis","volume":"14","author":"Flexner","year":"2019","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-018-3463-4","article-title":"A systematic review of adherence to oral pre-exposure prophylaxis for HIV \u2013 how can we improve uptake and adherence ?","volume":"18","author":"Sidebottom","year":"2018","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0045","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/QCO.0000000000000214","article-title":"Delivery of long-acting injectable antivirals: best approaches and recent advances","volume":"28","author":"Hickey","year":"2015","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0050","first-page":"781","article-title":"From sewer to saviour \u2014 targeting the lymphatic system to promote drug exposure and activity","volume":"14","author":"Trevaskis","year":"2015","journal-title":"Nat. Publ. Gr."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0055","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.biomaterials.2017.10.023","article-title":"Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles","volume":"151","author":"Zhou","year":"2018","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0060","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jconrel.2018.02.003","article-title":"Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation","volume":"275","author":"Kraft","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0065","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/COH.0000000000000002","article-title":"Long-acting injectable antiretrovirals for HIV treatment and prevention","volume":"8","author":"Spreen","year":"2013","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0070","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4155\/tde.15.4","article-title":"Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics","volume":"6","author":"Tatham","year":"2015","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0075","doi-asserted-by":"crossref","first-page":"182","DOI":"10.9745\/GHSP-D-17-00206","article-title":"Long-acting tretament and prevention: closer to the threshold","volume":"5","author":"Barnhart","year":"2017","journal-title":"Glob. Heal. Sci. Pract."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0080","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.tim.2019.02.009","article-title":"The promise of long-acting antiretroviral therapies: from need to manufacture","volume":"27","author":"Gendelman","year":"2019","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0085","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.addr.2016.02.003","article-title":"Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: insights for applications in HIV therapy","volume":"103","author":"Owen","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/psp.2013.41","article-title":"Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development","volume":"2","author":"Jones","year":"2013","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0095","first-page":"1","article-title":"Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development","volume":"2011","author":"Khalil","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2133\/dmpk.24.3","article-title":"Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling","volume":"24","author":"Ploeger","year":"2009","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0105","doi-asserted-by":"crossref","first-page":"21.1","DOI":"10.1146\/annurev.pharmtox.47.120505.105154","article-title":"Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis","volume":"47","author":"Danhof","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0110","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/infdis\/jiw637","article-title":"In vivo models of human immunodeficiency virus persistence and cure strategies","volume":"215","author":"Nixon","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0115","first-page":"2","article-title":"Exploring experimental animal models in HIV \/ AIDS research","volume":"2","author":"Sharma","year":"2013","journal-title":"Biochem. Anal. Biochem."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0120","first-page":"135","article-title":"Humanized mouse models of HIV infection","volume":"13","author":"Denton","year":"2011","journal-title":"AIDS Rev."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0125","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/imm.12906","article-title":"A Hitchhiker \u2019 s guide to humanized mice: new pathways to studying viral infections","volume":"154","author":"Skelton","year":"2018","journal-title":"Immunology."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-4690-10-121","article-title":"HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model","volume":"10","author":"Honeycutt","year":"2013","journal-title":"Retrovirology."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0135","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejpb.2018.04.014","article-title":"Recent developments of nanotherapeutics for targeted and long- acting, combination HIV chemotherapy","volume":"138","author":"Gao","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0140","series-title":"Prescribing Information for Genvoya","first-page":"1","year":"2016"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0155","series-title":"Summary of Product Characteristics","first-page":"1","year":"2020"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0160","article-title":"Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy","author":"Gao","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0190","author":"Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0250","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jconrel.2019.09.001","article-title":"Creation of a long-acting rilpivirine prodrug nanoformulation","volume":"311\u2013312","author":"Hilaire","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0255","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.biomaterials.2014.11.012","article-title":"Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations","volume":"41","author":"Puligujja","year":"2015","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0260","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/QAD.0000000000001349","article-title":"Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission","volume":"31","author":"Mandal","year":"2018","journal-title":"AIDS."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0265","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jconrel.2018.12.027","article-title":"Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: a comparative pre- exposure prophylaxis e ffi cacy study against HIV-1 vaginal transmission","volume":"294","author":"Mandal","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0270","doi-asserted-by":"crossref","first-page":"8371","DOI":"10.1039\/C8CC04708A","article-title":"ProTide generated long-acting abacavir nanoformulations","volume":"54","author":"Lin","year":"2018","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0275","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/COH.0000000000000374","article-title":"Universal Antiretroviral Regimens: Thinking Beyond One-Pill- Once-a-Day","volume":"12","author":"Jacobson","year":"2017","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0280","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5588\/ijtld.17.0486","article-title":"Long-acting formulations for the treatment of latent Tuberculosis infection: Opportunities and Challenges","volume":"22","author":"Swindells","year":"2018","journal-title":"Int J Tuberc Lung Dis."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0285","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/1061186X.2017.1419363","article-title":"Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook","volume":"26","author":"Mu","year":"2018","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0290","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/COH.0000000000000002","article-title":"Long-acting injectable antiretrovirals for HIV treatment and prevention","volume":"8","author":"Spreen","year":"2013","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0295","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0300","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1021\/ci100359a","article-title":"Automated selection of compounds with physicochemical properties to maximize bioavailability and druglikeness","volume":"51","author":"Oashi","year":"2012","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0305","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.chembiol.2014.08.013","article-title":"Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates","volume":"21","author":"Doak","year":"2014","journal-title":"Chem. Biol."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0310","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/mp500070m","article-title":"Making the leap from daily oral dosing to long-acting injectables: lessons from the antipsychotics","volume":"11","author":"Remenar","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0315","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.2147\/IJN.S215447","article-title":"Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation","volume":"14","author":"Ibrahim","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2019.119476","article-title":"A long acting nanoformulated lamivudine ProTide","volume":"223","author":"Smith","year":"2019","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0325","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1002\/jps.24046","article-title":"Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles","volume":"103","author":"Duan","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0330","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1128\/AAC.01529-09","article-title":"Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation","volume":"54","author":"Klooster","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0335","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1023\/A:1012188625088","article-title":"Polar molecular surface properties predict the intestinal absorption of drugs in humans","volume":"14","author":"Palm","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0340","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1208\/s12248-011-9290-9","article-title":"BDDCS applied to over 900 drugs","volume":"13","author":"Benet","year":"2011","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0345","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.addr.2016.05.007","article-title":"BDDCS, the rule of 5 and drugability","volume":"101","author":"Benet","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0350","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.addr.2007.10.012","article-title":"Biopharmaceutical challenges associated with drugs with low aqueous solubility \u2014 The potential impact of lipid-based formulations \u2606","volume":"60","author":"Driscoll","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics10030134","article-title":"Nanocrystals of poorly soluble drugs: drug bioavailability and physicochemical stability","volume":"10","author":"Gigliobianco","year":"2018","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-02294-6","article-title":"Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy","volume":"9","author":"Kirtane","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0365","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.biomaterials.2017.10.023","article-title":"Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles","volume":"151","author":"Zhou","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0370","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/14787210.2018.1430570","article-title":"Where are we with injectables against HIV infection and what are the remaining challenges?","volume":"16","author":"Hassounah","year":"2018","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0375","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.apsb.2018.07.011","article-title":"Parenteral nanosuspensions: a brief review from solubility enhancement to more novel and speci fi c applications","volume":"8","author":"Ahire","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0380","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejpb.2009.03.006","article-title":"Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment","volume":"72","author":"Baert","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0385","first-page":"1","article-title":"Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial","volume":"15","author":"Landovitz","year":"2018","journal-title":"PLOS Med. Med."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0390","series-title":"The Lymphatic Vasculature, in: Capill","author":"Scallan","year":"2010"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0395","first-page":"2733","article-title":"Advanced drug delivery to the lymphatic system: lipid-based nanoformulations","volume":"8","author":"Khan","year":"2013","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0400","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1146\/annurev-fluid-122316-045259","article-title":"Lymphatic system flows","volume":"50","author":"Moore","year":"2018","journal-title":"Annu. Rev. Fluid Mech."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0405","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.virol.2011.11.024","article-title":"Lymph nodes harbor viral reservoirs that cause rebound of plasma viremia in SIV-infected macaques upon cessation of combined antiretroviral therapy","volume":"423","author":"Horiike","year":"2012","journal-title":"Virology."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0410","series-title":"The Lymph Node in HIV Pathogenesis, Curr HIV\/AIDS Rep","author":"Dimopoulos","year":"2017"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0415","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijpharm.2016.05.034","article-title":"Polyaminoacid nanocapsules for drug delivery to the lymphatic system: effect of the particle size","volume":"509","author":"Abell","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0420","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0166-3542(02)00052-9","article-title":"Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir","volume":"55","author":"Aquaro","year":"2002","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0425","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1023\/A:1015852732512","article-title":"Phagocytosis of Nanoparticles by Human Immunodeficiency Virus (HIV)-Infected Macrophages: A Possibility for Antiviral Drug Targeting","volume":"9","author":"Schafer","year":"1992","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0430","first-page":"99","article-title":"Pharmacokinetics and tissue distribution of zidovudine in rats following intravenous administration of zidovudine myristate loaded liposomes","volume":"60","author":"Jin","year":"2005","journal-title":"Pharmazie."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0435","doi-asserted-by":"crossref","first-page":"661","DOI":"10.4049\/jimmunol.0900274","article-title":"Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS","volume":"183","author":"Dou","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0145966","article-title":"Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy","volume":"10","author":"Martinez-skinner","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0445","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1128\/AAC.00267-13","article-title":"Preclinical Pharmacokinetics and Tissue Distribution of Long-Acting Nanoformulated Antiretroviral Therapy","volume":"57","author":"Gautam","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0450","article-title":"Towards a Maraviroc long-acting injectable nanoformulation","author":"Tatham","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0455","first-page":"1","article-title":"Three HIV drugs, atazanavir, ritonavir, and tenofovir, coformulated in drug-combination nanoparticles exhibit long-acting and lymphocyte-targeting properties in nonhuman primates","volume":"101","author":"Perazzolo","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0460","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1089\/aid.2014.0210","article-title":"Anti-HIV drug-combination nanoparticles enhance as well as triple-drug combination levels in cells within lymph nodes and blood in primates","volume":"31","author":"Freeling","year":"2015","journal-title":"AIDS Res. Hum. Retrviruses."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0465","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1097\/QAD.0000000000000421","article-title":"Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood","volume":"28","author":"Freeling","year":"2014","journal-title":"AIDS."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0470","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.antiviral.2019.04.010","article-title":"Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIV","volume":"167","author":"Kudalkar","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0475","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.06.005","article-title":"Long-acting parenteral combination antiretroviral loaded nano-drug delivery system to treat chronic HIV-1 infection: A humanized mouse model study","volume":"156","author":"Mandal","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0480","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/COH.0000000000000168","article-title":"Formulation and pharmacology of long-acting cabotegravir","volume":"10","author":"Trezza","year":"2015","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0485","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/COH.0000000000000164","article-title":"Formulation and pharmacology of long-acting rilpivirine","volume":"10","author":"Williams","year":"2015","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0490","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.apsb.2015.11.005","article-title":"Injected nanocrystals for targeted drug delivery","volume":"6","author":"Lu","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0495","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2147\/NDT.S3311","article-title":"Risperidone long-acting injection: a review of its long term safety and ef fi cacy","volume":"4","author":"Rainer","year":"2008","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0500","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/TCRM.S81581","article-title":"A critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorder","volume":"12","author":"Chue","year":"2016","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0505","first-page":"261","article-title":"Long-acting injectable antipsychotics: focus on olanzapine pamoate","volume":"6","author":"Lindenmayer","year":"2010","journal-title":"Neurol. Res."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0510","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/btm2.10096","article-title":"Harnessing nanostructured systems for improved treatment and prevention of HIV disease","volume":"3","author":"Monroe","year":"2018","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph12020062","article-title":"Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase","volume":"12","author":"Singh","year":"2019","journal-title":"Pharmaceuticals."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0520","first-page":"1","article-title":"Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion betw","author":"Bowers","year":"2015","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0525","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jconrel.2017.10.017","article-title":"Multimodal imaging approach to examine biodistribution kinetics of Cabotegravir (GSK1265744) long acting parenteral formulation in rat","volume":"268","author":"Jucker","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0530","article-title":"Pharmacokinetics and pharmacodynamics of cabotegravir, a long - acting hiv integrase strand transfer inhibitor","author":"Cattaneo","year":"2018","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0535","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/QAD.0000000000001343","article-title":"Cabotegravir long-acting injection protects macaques against intravenous challenge with SIVmac251","volume":"31","author":"Andrews","year":"2017","journal-title":"AIDS."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0540","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010298","article-title":"A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge","volume":"7","author":"Andrews","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0555","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/hiv.12716","article-title":"Two-drug vs. three-drug combinations for HIV-1: do we have enough data to make the switch ?","volume":"20","author":"Moreno","year":"2019","journal-title":"HIV Med."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0560","author":"HPTN"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0565","first-page":"1","article-title":"Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076)","volume":"22","author":"Hptn","year":"2019","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0570","author":"Safety"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0575","first-page":"1","article-title":"Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial","author":"Markowitz","year":"2017","journal-title":"Lancet HIV."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0585","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/hiv.12247","article-title":"Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers *","volume":"16","author":"Verloes","year":"2015","journal-title":"HIV Med."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0590","first-page":"1","article-title":"Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment","volume":"3018","author":"Mcgowan","year":"2016","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0595","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/QAI.0000000000000301","article-title":"GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects","volume":"67","author":"Spreen","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0605","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/cpdd.664","article-title":"A phase i study to evaluate the pharmacokinetics and safety of cabotegravir in adults with severe renal impairment and healthy","volume":"8","author":"Parasrampuria","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0620","first-page":"1","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"6736","author":"Margolis","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0625","series-title":"Conf. Retroviruses Opportunistic Infect","article-title":"Long-acting Cabotegravir + Rilpivirine as maintenance therapy: ATLAS week 48 results","author":"Susan","year":"2019"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0635","series-title":"Conf. Retroviruses Opportunistic Infect","article-title":"Long-acting Cabotegravir+Rilpivirne for HIV maintenance: FLAIR week 48 results","author":"Orkin","year":"2019"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0655","series-title":"How Solid Drug Nanoparticles Can Tackle Drug Adherence Issues","first-page":"4","author":"Critchley","year":"2018"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0660","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2147\/IJN.S38378","article-title":"Nanodrugs: pharmacokinetics and safety","volume":"9","author":"Onoue","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0665","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/adhm.201300280","article-title":"Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro \u2013 in vivo correlation","volume":"3","author":"Mcdonald","year":"2014","journal-title":"Adv. Heal. Mater."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0670","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/jin2.21","article-title":"Towards a rational design of solid drug nanoparticles with optimised pharmacological properties","volume":"1","author":"Siccardi","year":"2016","journal-title":"J. Interdiscip. Nanomed."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0675","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejpb.2018.05.015","article-title":"Improving maraviroc oral bioavailability by formation of solid drug nanoparticles","volume":"138","author":"Savage","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0680","author":"London"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0685","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/infdis\/jis395","article-title":"Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1 \u2013 infected human peripheral blood lymphocyte \u2013 reconstituted mice","volume":"206","author":"Roy","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0690","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1021\/acs.molpharmaceut.9b00871","article-title":"Synthesis and characterization of long-acting darunavir prodrugs","volume":"17","author":"Banoub","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0695","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/QAI.0000000000001170","article-title":"Creation of a long-acting nanoformulated 2\u2019,3\u2019-dideoxy-3\u2019-thiacytidine","volume":"74","author":"Guo","year":"2017","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0700","first-page":"1","article-title":"Creation of a long-acting nanoformulated dolutegravir","volume":"9","author":"Brady Sillman","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0705","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.2042-7158.2012.01482.x","article-title":"Accelerated in-vitro release testing methods for extended-release parenteral dosage forms","volume":"64","author":"Shen","year":"2012","journal-title":"J. Pharm. Pharamcol."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0710","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/jps.2600760902","article-title":"Hydrophobicity and central nervous system agents: On the principle of minimal hydrophobicity in drug deisgn","volume":"76","author":"Hansch","year":"1987","journal-title":"J. Pharamceutical Sci."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0715","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01475-16","article-title":"An enhanced emtricitabine-loaded long-acting nanoformulation for prevention or treatment of hiv infection","volume":"61","author":"Mandal","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0720","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.antiviral.2019.04.007","article-title":"A potential long-acting bictegravir loaded nano-drug delivery system for HIV-1 infection: a proof-of-concept study","volume":"167","author":"Mandal","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0725","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1007\/s11095-017-2255-7","article-title":"Pharmacokinetic and tissue distribution profile of long acting tenofovir alafenamide and elvitegravir loaded nanoparticles in humanized mice model","volume":"34","author":"Prathipati","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0735","first-page":"107","article-title":"Lipid nanoparticulate drug delivery systems: a revolution in dosage form design and development","author":"Attama","year":"2012","journal-title":"Recent Adv. Nov. Drug Carr. Syst."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0740","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jddst.2017.02.013","article-title":"Development of efavirenz loaded solid lipid nanoparticles: Risk assessment, quality-by-design (QbD) based optimisation and physicochemical characterisation","volume":"39","author":"Raina","year":"2017","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0745","doi-asserted-by":"crossref","first-page":"112765","DOI":"10.1016\/j.jpba.2019.07.013","article-title":"Development and validation of reverse-phase high-performance liquid chromatographic (RP-HPLC) method for quantification of Efavirenz in Efavirenz-Enfuvirtide co-loaded polymer-lipid hybrid nanoparticles","volume":"175","author":"Surve","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0750","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms19123859","article-title":"A promising biocompatible platform: lipid-based and bio-inspired smart drug delivery systems for cancer therapy","volume":"19","author":"Kim","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0755","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2014.05.042","article-title":"Conventional versus stealth lipid nanoparticles: Formulation and in vivo fate prediction through FRET monitoring","volume":"188","author":"Laine","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0760","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijpharm.2017.02.024","article-title":"In situ hybrid nano drug delivery system (IHN-DDS) of antiretroviral drug for simultaneous targeting to multiple viral reservoirs: An in vivo proof of concept","volume":"521","author":"Jindal","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0765","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1002\/jps.22052","article-title":"Particle shape: a new design parameter for passive targeting in splenotropic drug delivery","volume":"99","author":"Devarajan","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0770","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s13346-016-0304-0","article-title":"Nanocarriers for spleen targeting: anatomo-physiological considerations, formulation strategies and therapeutic potential","volume":"6","author":"Jindal","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0775","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ijpharm.2017.09.028","article-title":"The effect of particle shape on cellular interaction and drug delivery applications of micro- and nanoparticles","volume":"532","author":"Jindal","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0780","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1073\/pnas.0600997103","article-title":"Role of target geometry in phagocytosis","volume":"103","author":"Champion","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0785","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0010051","article-title":"Macrophages recognize size and shape of their targets","volume":"5","author":"Doshi","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0790","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jconrel.2010.07.116","article-title":"Polymer particle shape independently influences binding and internalization by macrophages","volume":"147","author":"Sharma","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0795","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1097\/QAD.0b013e328357f5ad","article-title":"Long-acting NanoART elicits potent antiretroviral and neuroprotective responses in HIV-1 infected humanized mice","volume":"26","author":"Dash","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0800","doi-asserted-by":"crossref","first-page":"630","DOI":"10.7150\/thno.39847","article-title":"Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues","volume":"10","author":"Kevadiya","year":"2020","journal-title":"Theronostics."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0805","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01316-17","article-title":"Pharmacokinetics of a long-acting nanoformulated dolutegravir prodrug in rhesus macaques","volume":"62","author":"McMillan","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0810","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-09354-z","article-title":"Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies","volume":"10","author":"Hobson","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0815","first-page":"1","article-title":"From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection","author":"Kudalkar","year":"2017","journal-title":"PNAS PLUS"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0820","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40262-014-0227-1","article-title":"Physiologically-based pharmacokinetic modelling to inform development of intramuscular long acting nanoformulations for HIV","volume":"54","author":"Rajoli","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0825","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40262-017-0557-x","article-title":"In silico dose prediction for long-acting rilpivirine and cabotegravir administration to children and adolescents","volume":"57","author":"Rajoli","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0830","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejpb.2019.09.011","article-title":"Modelling the intradermal delivery of microneedle array patches for long- acting antiretrovirals using PBPK","volume":"144","author":"Rajoli","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0835","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.addr.2018.08.013","article-title":"Physiologically based pharmacokinetic modelling to guide drug delivery in older people","volume":"135","author":"Chetty","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0840","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.tips.2008.01.007","article-title":"Mechanism-based pharmacokinetic- pharmacodynamic (PK-PD) modeling in translational drug research","volume":"29","author":"Danhof","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0845","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.2353\/ajpath.2010.100536","article-title":"Links between progressive HIV-1 infection of humanized mice and viral neuropathogenesis","volume":"177","author":"Gorantla","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0850","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jconrel.2018.12.027","article-title":"Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre- exposure prophylaxis e ffi cacy study against HIV-1 vaginal transmission","volume":"294","author":"Mandal","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0855","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nm.4319","article-title":"HIV persistence in tissue macrophages of humanized myeloid only mice during antiretroviral therapy","volume":"23","author":"Honeycutt","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0860","first-page":"87","article-title":"Humanized NSG mouse models of HIV-1 infection and pathogenesis","volume":"3","author":"Latinovic","year":"2016","journal-title":"J. Hum. Virol. Retrovirol."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0865","first-page":"1","article-title":"Humanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti- retroviral drugs for treating HIV-1","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0870","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2016.00012","article-title":"Animal models for Hiv cure research","volume":"7","author":"Policicchio","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0875","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S0966-842X(00)01816-3","article-title":"The chimpanzee and other non-human-primate models in HIV-1 vaccine research","volume":"8","author":"Nath","year":"2000","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0880","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nrmicro2911","article-title":"Animal models for HIV\/AIDS research","volume":"10","author":"Hatziioannou","year":"2012","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0885","first-page":"259","article-title":"Tackling HIV and AIDS: contributions by non-human primate models","volume":"46","author":"Koen","year":"2017","journal-title":"Nat. Publ. Gr."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0890","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/COH.0000000000000152","article-title":"Animal models in HIV-1 protection and therapy","volume":"10","author":"Hessell","year":"2015","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0895","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-4690-5-94","article-title":"SHIV-1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys","volume":"5","author":"Humbert","year":"2008","journal-title":"Retroviro."},{"key":"10.1016\/j.jconrel.2020.05.022_bb0900","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1208\/s12249-014-0177-9","article-title":"Nanomedicine scale-up technologies: feasibilities and challenges","volume":"15","author":"Paliwal","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0905","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1208\/s12248-012-9339-4","article-title":"Challenges in development of nanoparticle-based therapeutics","volume":"14","author":"Desai","year":"2012","journal-title":"J. AAPS"},{"key":"10.1016\/j.jconrel.2020.05.022_bb0910","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-10366-y","article-title":"Sequential LASER ART and CRISPR treatments mice","volume":"10","author":"Dash","year":"2019","journal-title":"Nat. Commun."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920302996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920302996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:51:27Z","timestamp":1759161087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365920302996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":153,"alternative-id":["S0168365920302996"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.05.022","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}